LL-37

The honest framing of LL-37 sits between four facts that the practitioner literature usually conflates. The mechanism work is decades deep and substantively replicated across independent laboratories — the antimicrobial, chemotactic, angiogenic, and vitamin-D-axis lines are all anchored in top-journal papers from the 2000–2010 window. The human-RCT evidence base for exogenous LL-37 administration in any condition is essentially confined to topical / wound and ototopical indications using engineered analogs rather than native LL-37, and even those programs are small. The systemic gray-market subcutaneous use case that drives current biohacker interest — chronic infection, autoimmunity flares, post-Lyme, biofilm-associated infection, chronic sinusitis — has no controlled trial evidence at all. And the same biology that makes the molecule attractive in chronic-infection framing is the biology implicated in psoriasis, lupus, rosacea, and atherosclerosis pathology when it goes wrong.

The chronic-infection / biofilm case is the most mechanistically plausible biohacker framing. LL-37 has documented activity against biofilms at sub-MIC concentrations, demonstrated synergy with conventional antibiotics in vitro, and a role in airway defense, urinary tract immunity, and skin innate immunity (Ridyard & Overhage, Antibiotics 2021, 10:650). The translation gap is real and large: native LL-37 is rapidly degraded in plasma and reaches low free concentrations after systemic dosing; cost of synthesis is high; activity is attenuated in physiological salt and serum conditions; and the engineered analogs that overcome those limitations (OP-145, LTX-109, others) are not chemically equivalent to native LL-37 and carry their own pharmacology. The most relevant controlled clinical translation in 2026 remains Peek et al., PLoS One 2020, 15:e0231573 — a 34-subject Phase IIa double-blinded placebo-controlled trial of the LL-37 derivative OP-145 as ototopical drops in chronic suppurative otitis media, reporting 47% treatment success vs 6% placebo with a favourable safety profile. That is the high-water mark of clinical evidence for the entire LL-37 family: a small Phase II in an ototopical indication, using a chemically modified analog, not the parent peptide injected systemically.

The wound-healing case is mechanistically anchored by Koczulla et al. 2003 on angiogenesis and by the broader epithelial-proliferation literature, and the molecule is sometimes cross-referenced against BPC-157 and TB-500 in the practitioner conversation around soft-tissue repair. The cross-reference is honest at the mechanism level — VEGF / FPR2 endothelial signalling, recruited-leukocyte support, capillary tube formation — and overreaches at the human-outcome level, where the LL-37 record is essentially preclinical. The /dossiers/healing-and-angiogenesis dossier covers the comparative framing.

The autoimmunity literature is the side of LL-37 that the marketing-tier framing systematically understates, and that the careful reader needs to internalise before any chronic-use decision. Lande et al., Nature 2007, 449:564–569 showed that LL-37 complexes with self-DNA in psoriatic skin, condensing the DNA into structures that are retained in plasmacytoid-dendritic-cell endocytic compartments long enough to trigger TLR9 and drive type I interferon production. Psoriasis-relevant pDC activation, in this model, is essentially LL-37-dependent. Yamasaki et al., Nature Medicine 2007, 13:975–980 extended the same biology into rosacea: rosacea patients express abnormally high cathelicidin, with aberrant kallikrein-5-mediated proteolytic processing producing pro-inflammatory LL-37 fragments not seen in normal skin. The Kahlenberg & Kaplan, J Immunol 2013, 191:4895–4901 review consolidated the picture across atopic dermatitis, psoriasis, systemic lupus erythematosus, rheumatoid arthritis, and atherosclerosis — LL-37 as the inflammatory peptide whose dysregulation contributes to a recognisable cluster of autoimmune and chronic inflammatory diseases. The mast-cell branch of this same biology runs through MRGPRX2: LL-37 directly activates human mast cells via this G-protein-coupled receptor and is implicated in rosacea-pattern skin inflammation and histaminergic symptom amplification, which is the mechanistic basis for the concern that exogenous LL-37 in a mast-cell-activation-syndrome phenotype can worsen rather than help.

Several adjacent peptides in the corpus carry related immune biology and warrant comparison rather than substitution. KPV sits in a different anti-inflammatory mechanism altogether — NF-κB suppression and PepT1-mediated mucosal uptake — and is the more mechanistically conservative choice when the goal is mucosal-inflammation calming. Thymosin α-1 addresses T-cell exhaustion and innate-immunity homeostasis in chronic viral and post-viral settings and carries an actual approved-product clinical track record across 35+ countries. The /dossiers/long-covid-and-peptides dossier covers where LL-37 sits in the post-viral immune-recovery conversation: theoretically attractive on mechanism, essentially absent from the controlled clinical evidence base.